You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

134 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Aug 2020
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
May 2025
Drug
Other Name(s): Cabometyx®
May 2025
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
May 2025
Drug
Other Name(s): Erwinase®
Jan 2020
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Aug 2020
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Curative, Palliative
Mar 2020

Pages